Alliancebernstein L.P. decreased its position in Boston Scientific Co. (NYSE:BSX) by 2.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,226,854 shares of the medical equipment provider’s stock after selling 53,043 shares during the period. Alliancebernstein L.P. owned about 0.16% of Boston Scientific worth $55,204,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. Delpha Capital Management LLC bought a new stake in Boston Scientific in the fourth quarter valued at $135,000. Landscape Capital Management L.L.C. bought a new stake in Boston Scientific in the fourth quarter valued at $1,171,000. Geode Capital Management LLC boosted its holdings in Boston Scientific by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 13,040,987 shares of the medical equipment provider’s stock valued at $322,533,000 after acquiring an additional 373,607 shares in the last quarter. Dorsey & Whitney Trust CO LLC bought a new stake in Boston Scientific in the fourth quarter valued at $207,000. Finally, Icon Wealth Partners LLC bought a new stake in Boston Scientific in the fourth quarter valued at $117,000. Hedge funds and other institutional investors own 91.85% of the company’s stock.
Boston Scientific Co. (BSX) opened at $28.54 on Tuesday. The company has a current ratio of 0.68, a quick ratio of 0.49 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $39,240.00, a price-to-earnings ratio of 40.77, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82. Boston Scientific Co. has a 52-week low of $24.02 and a 52-week high of $29.93.
Several analysts recently weighed in on BSX shares. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. BMO Capital Markets reiterated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a report on Wednesday, November 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Boston Scientific in a report on Wednesday, November 29th. Canaccord Genuity cut their price target on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, November 29th. Finally, SunTrust Banks set a $33.00 price target on shares of Boston Scientific and gave the company a “buy” rating in a report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.06.
In other news, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the transaction, the senior vice president now owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $27.43, for a total value of $53,488.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,276 shares of company stock valued at $4,592,464. 0.74% of the stock is owned by insiders.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.